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Objectives
Advances in human genome studies resulted in identifi-
cation of numerous genes which, if mutated, provoke
monogenic disorders of different kind or can contribute
to a number of complex diseases (CD). While basic pro-
blems of monogenic disorders are already solved the
genetic impact into CDs seems to be illusive so far in
the most cases and remains a cumber-stone of currant
PPPM. Technology Identification of candidate genes
associated with complex diseases by genetic testing,
linkage studies and GWAS approach resulted in rele-
vant genetic panels specific for each of many CDs. How-
ever diagnostic value of these panels remains obscure
for the most of known CDs so far. Individual genetic
data contributing to human health as well as to the
onset of a CD are quickly accumulated in Individual
DNA -data bank, which could be interpreted as Indivi-
dual Gene-Pass (IGP).
Results
Associated gene studies already substantiated the issue
of Gene-pass of Reproductive Health (GPRH). It consists
of two mandatory parts of genetic testing results. The
first - carriers testing in spouses for sever monogenic
diseases. The second - the panels of candidate genes
associated with preeclampsia, endometriosis, trombophi-
lia, habitual abortions, diabetes, nerve tube defects chro-
mosome non - disjunction, placenta insufficiency, as
well as some pharmacogenetic tests elaborated for preg-
nant women. GPRH at use in our institute will be
demonstrated. The genetic data together with relevant
laboratory tests extrapolated to individual case history
after sophisticated bioinformatic analysis (MDR test) are
used for prospective individual risk evaluation.
Outlook and expert recommendations
In spite on huge progress of whole genome sequencing
it will never substitute the clinically important IGP
incorporating only health meaningful genes and associa-
tions Suggested GPRH is the only one of many other
IGPs already existing de facto. Genetic data supplemen-
ted with epigenetic information contributing to regula-
tion of associated gene expression should be considered
the next important step towards System Genetic Level
of CD studies for PPPM purposes.
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